SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. Financials Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Equities
6990
CNE1000062J1
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 171 HKD | -1.04% |
|
-0.70% | +66.18% |
| 06-21 | Sichuan Kelun-Biotech Directors Approve Full Circulation of H-Shares | MT |
| 06-18 | Hong Kong Shares Fall on Weak Economic Data, Trade Tensions; Wuhan Youji Surges 27% in Trading Debut | MT |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 20,501 | 35,823 | - | - |
| Enterprise Value (EV) 2 | 19,042 | 35,248 | 35,049 | 34,848 |
| P/E ratio | -33.4 x | -59.2 x | -55.6 x | -624 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 13.3 x | 30.7 x | 23.1 x | 14 x |
| EV / Revenue | 12.4 x | 30.2 x | 22.6 x | 13.6 x |
| EV / EBITDA | -57.9 x | -64.7 x | -67.3 x | 127 x |
| EV / FCF | -839 x | -40.1 x | -52.8 x | -188 x |
| FCF Yield | -0.12% | -2.5% | -1.89% | -0.53% |
| Price to Book | 7.48 x | 20.9 x | 30.5 x | 18.6 x |
| Nbr of stocks (in thousands) | 219,195 | 222,844 | - | - |
| Reference price 3 | 102.9 | 172.8 | 172.8 | 172.8 |
| Announcement Date | 25/03/24 | - | - | - |
1HKD in Million2CNY in Million3HKD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 1,540 | 1,166 | 1,548 | 2,559 |
| EBITDA 1 | - | -328.6 | -544.9 | -520.7 | 274.7 |
| EBIT 1 | - | -383.4 | -670.5 | -715.4 | -213.3 |
| Operating Margin | - | -24.89% | -57.5% | -46.23% | -8.33% |
| Earnings before Tax (EBT) 1 | - | -467.7 | -594.4 | -598.6 | -0.214 |
| Net income 1 | -616.1 | -574.1 | -570.5 | -608.6 | -33.81 |
| Net margin | - | -37.27% | -48.93% | -39.32% | -1.32% |
| EPS 2 | -6.201 | -3.080 | -2.917 | -3.108 | -0.2769 |
| Free Cash Flow 1 | - | -22.69 | -879.9 | -663.4 | -184.9 |
| FCF margin | - | -1.47% | -75.46% | -42.87% | -7.23% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 28/06/23 | 25/03/24 | - | - | - |
1CNY in Million2HKD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|
| Net sales 1 | 1,046 | 494.3 | 854.8 | 663 |
| EBITDA | - | - | - | - |
| EBIT 1 | 95.89 | -503.4 | -179 | -642.3 |
| Operating Margin | 9.17% | -101.85% | -20.94% | -96.88% |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income | - | - | - | - |
| Net margin | - | - | - | - |
| EPS 2 | -0.1829 | -2.896 | -1.170 | -3.270 |
| Dividend per Share | - | - | - | - |
| Announcement Date | 28/08/23 | 25/03/24 | - | - |
1CNY in Million2HKD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 1,459 | 575 | 774 | 975 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -22.7 | -880 | -663 | -185 |
| ROE (net income / shareholders' equity) | - | - | -30.2% | -65.8% | -22.8% |
| ROA (Net income/ Total Assets) | - | -25.5% | -23.4% | -25.1% | 7.34% |
| Assets 1 | - | 2,251 | 2,440 | 2,428 | -460.6 |
| Book Value Per Share 2 | - | 13.80 | 8.260 | 5.660 | 9.300 |
| Cash Flow per Share 2 | - | 0.3500 | -2.900 | -0.2400 | 4.910 |
| Capex 1 | - | 82.3 | 133 | 140 | 143 |
| Capex / Sales | - | 5.34% | 11.4% | 9.04% | 5.57% |
| Announcement Date | 28/06/23 | 25/03/24 | - | - | - |
1CNY in Million2HKD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
172.8
HKD
Average target price
201.4
HKD
Spread / Average Target
+16.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +66.18% | 4.93B | |
| +15.19% | 121B | |
| +19.91% | 114B | |
| +18.37% | 23.61B | |
| -19.80% | 20.43B | |
| -15.73% | 16.55B | |
| -13.45% | 16.45B | |
| -44.35% | 15.59B | |
| +66.67% | 15.19B | |
| +2.13% | 13.54B |
- Stock Market
- Equities
- 6990 Stock
- Financials Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
